Vascular access-related thrombotic complications: Research hypotheses and therapeutic strategies

Simona Bruno, G. Remuzzi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.

Original languageEnglish
Pages (from-to)280-285
Number of pages6
JournalJournal of Nephrology
Volume19
Issue number3
Publication statusPublished - May 2006

Fingerprint

Therapeutic Human Experimentation
clopidogrel
Blood Vessels
Thrombosis
Heparinoids
Adrenergic alpha-Antagonists
Investigational Therapies
Fish Oils
Platelet Aggregation Inhibitors
Coenzymes
Calcium Channel Blockers
Homocysteine
Renin-Angiotensin System
Reoperation
Angioplasty
Genetic Therapy
Stents
Oxidoreductases
Pathologic Constriction
Radiotherapy

ASJC Scopus subject areas

  • Nephrology

Cite this

Vascular access-related thrombotic complications : Research hypotheses and therapeutic strategies. / Bruno, Simona; Remuzzi, G.

In: Journal of Nephrology, Vol. 19, No. 3, 05.2006, p. 280-285.

Research output: Contribution to journalArticle

@article{88c48238a20143f9b98a81efc3dc1999,
title = "Vascular access-related thrombotic complications: Research hypotheses and therapeutic strategies",
abstract = "The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85{\%} of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.",
author = "Simona Bruno and G. Remuzzi",
year = "2006",
month = "5",
language = "English",
volume = "19",
pages = "280--285",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Vascular access-related thrombotic complications

T2 - Research hypotheses and therapeutic strategies

AU - Bruno, Simona

AU - Remuzzi, G.

PY - 2006/5

Y1 - 2006/5

N2 - The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.

AB - The most common complication of permanent vascular access is thrombosis, which accounts for 80 to 85% of AV access loss. Treatment of venous stenosis by percutaneous angioplasty, endovascular stents and surgical revision is clinically important but many strategies to prevent thrombosis have been employed, such as antiplatelet agents, systemic anticoagulation, and experimental therapies as fish oils, heparinoids, clopidogrel, renin-angiotensin system antagonists, calcium channel blockers, alpha adrenergic antagonists, homocysteine-lowering agents and beta-hydroxybetamethyglutaryl coenzyme-A reductase inhibitors. Future but promising approaches are endovascular radiation and gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=33749077325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749077325&partnerID=8YFLogxK

M3 - Article

C2 - 16874686

AN - SCOPUS:33749077325

VL - 19

SP - 280

EP - 285

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 3

ER -